Brief: Abivax Presents First Quarter 2026 Financial Results
22/05/2026 21:13
May 22 (Reuters) - Abivax SA ABVX.PA: ABIVAX PRESENTS FIRST QUARTER 2026 FINANCIAL RESULTS AND REPORTS THREE-YEAR INTERIM DATA FROM STUDY 108, A PHASE 2A/2B OPEN-LABEL EXTENSION TRIAL OF OBEFAZIMOD FOLLOWING DOSE DE-ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS ABIVAX SA - REPORTS CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF €491.6 MILLION AS OF MARCH 31, 2026 ABIVAX SA - Q1 2026 OPERATING LOSS WAS €56.2 MILLION ABIVAX SA - Q1 NET LOSS 48.5 MILLION EUROS Source text: ID:nGNXf949j Further company coverage: ABVX.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abivax SA
See all newsAbivax shares fall after rival drug data, trader says
France's Abivax H1 net loss widens on higher expenses driven by clinical programs
U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United Rentals
GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate
Europe's STOXX 600 ends week at all-time high on earnings support, soft US jobs data